Theriva Biologics, Inc.
Price Action
Technical Summary
CONSOLIDATINGTheriva Biologics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 91), indicating clear outperformance against the broad market. Earnings growth of 97% provides fundamental context to the price action. However, price is extended 41% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $0.33 | +8.17% | ABOVE |
| 50 SMA | $0.26 | +40.85% | ABOVE |
| 100 SMA | $0.23 | +58.38% | ABOVE |
| 150 SMA | $0.26 | +39.53% | ABOVE |
| 200 SMA | $0.30 | +20.48% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is TOVX in an uptrend right now?
TOVX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is TOVX overbought or oversold?
TOVX's RSI (14) is 60. The stock is in neutral territory, neither overbought nor oversold.
Is TOVX outperforming the market?
TOVX has a Relative Strength (RS) Rating of 91 out of 99. Yes, TOVX is a market leader, outperforming 91% of all stocks over the past 12 months.
Where is TOVX in its 52-week range?
TOVX is trading at $0.36, which is 42% of its 52-week high ($0.86) and 28% above its 52-week low ($0.16).
How volatile is TOVX?
TOVX has a Beta of 2.08 and 52-week volatility of 168%. It's more volatile than the S&P 500 - expect bigger swings.